

**Date:** May 14, 2026

To,  
Sr. General Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

**BSE Scrip Code: 544319**

To,  
Sr. General Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**

**Sub.: Submission of statement of Deviation or Variation in utilisation of funds of public issue for quarter ended on March 31, 2026.**

Dear Sir/Madam,

Pursuant to Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, please find enclosed herewith the statement of deviation(s) or variation(s) in utilisation of funds raised through Initial Public Offer (“IPO”) by the Company for the quarter ended March 31, 2026.

We hereby confirm that there has been no deviation(s) or variation(s) in the utilization of proceeds of IPO for the abovementioned period as mentioned in the objects stated in the Prospectus dated December 24, 2024.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on May 14, 2026.

This intimation is also being uploaded on the website of the Company i.e. [www.senorespharma.com](http://www.senorespharma.com).

You are requested to take the same on record.

Thanking you.

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**  
Company Secretary and Compliance Officer  
ICSI Membership No.: F11464

**Enclosure:** As above

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

**STATEMENT OF DEVIATION(S) / VARIATION(S) IN UTILISATION OF FUNDS RAISED THROUGH IPO, FOR THE QUARTER ENDED MARCH 31, 2026**

<b>Name of listed entity</b>	Senores Pharmaceuticals Limited
<b>Mode of Fund Raising</b>	Initial Public offer
<b>Date of Raising Funds</b>	December 26, 2024
<b>Amount Raised</b>	Rs. 500 Crores
<b>Report filed for Quarter ended</b>	March 31, 2026
<b>Monitoring Agency</b>	Applicable
<b>Monitoring Agency Name, if applicable</b>	CARE Ratings Limited
<b>Is there a Deviation / Variation in use of funds raised</b>	No
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	Not Applicable
<b>If Yes, Date of shareholder Approval</b>	Not Applicable
<b>Explanation for the Deviation / Variation</b>	Not Applicable
<b>Comments of the Audit Committee after review</b>	No comments
<b>Comments of the auditors, if any</b>	No comments

<b>Objects for which funds have been raised and where there has been a deviation, in the following table</b>						
<b>Original Object</b>	<b>Modified Object, if any</b>	<b>Original Allocation</b>	<b>Modified Allocation, if any</b>	<b>Funds Utilized</b>	<b>Amount of Deviation/ Variation for the quarter according to applicable object</b>	<b>Remarks, if any</b>
Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections	Not Applicable	107.00	Not Applicable	6.98	Not Applicable	There is ongoing delay in deployment of funds under object-1 to the extent of Rs. 33.02 crores as the company has utilized IPO proceeds of

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

in our Atlanta Facility						Rs. 6.98 crore against scheduled deployment of Rs. 40 crore in Fiscal 2026 due to ongoing geopolitical issues. Hence, the company has taken management committee approval on March 03, 2026 to utilize the same by Fiscal 2027.
Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company	Not Applicable	73.48	73.10	73.10	Not Applicable	The unutilized amount of Rs. 0.38 crore has been transferred to GCP as resolved in the Board Meeting dated July 23, 2025.
Investment in our Subsidiary, namely, Havix, for re-payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	Not Applicable	20.22	20.20	20.20	Not Applicable	The unutilized amount of Rs. 0.02 crore has been transferred to GCP as resolved in the Board Meeting dated July 23, 2025
Funding the working capital requirements of our Company	Not Applicable	43.26	Not Applicable	43.26	Not Applicable	Utilized towards working capital by transferring

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

 W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

						to OD/CC accounts of SPL
Investment in our Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements	Not Applicable	59.48	Not Applicable	59.48	Not Applicable	Utilized by way of transfer of funds to OD/CC accounts of Ratnatris. The company has utilized ₹26.98 crore and ₹32.50 crore towards funding the working capital requirements of Ratnatris and SPI, respectively, against the proposed utilization of ₹30.66 crore and ₹28.82 crore as per the prospectus. However, the utilization has remained within the overall amount earmarked under this objective.
Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes	Not Applicable	154.37	161.07	157.16	Not Applicable	Amount of Rs. 6.70 crore has been transferred from Objective 2, 3 and 7.
Offer expenses	Not Applicable	42.19	35.88	34.80	Not Applicable	The unutilized

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

 W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

						amount of Rs. 6.31 crore has been transferred to objective-6 as resolved in the Board Meeting dt. March 28, 2026.
<b>Total</b>		<b>500.00</b>		<b>394.98</b>		

**Deviation or variation could mean:**

- (a) Deviation in the objects or purposes for which the funds have been raised; or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or
- (c) Change in terms of a contract referred to in the fund-raising documents i.e, prospectus, letter of offer, etc

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**

Company Secretary and Compliance Officer

ICSI Membership No.: F11464

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263